Company Overview - Boston Scientific, Inc. (BSX) has signed a definitive agreement to acquire SoniVie Ltd., a privately held medical device company, for nearly $360 million upfront, with an additional $180 million contingent on regulatory milestones [1] - The transaction is expected to close in the first half of 2025, subject to customary closing conditions [1] Stock Performance - Following the acquisition announcement, BSX shares rose 1% to finish at $104.87 [2] - Over the past year, Boston Scientific shares have increased by 55.5%, compared to the industry's growth of 11.8% [10] Financial Metrics - Boston Scientific has a market capitalization of $153.17 billion [3] - The Zacks Consensus Estimate for the company's 2025 earnings per share (EPS) is $2.85, indicating a 13.6% year-over-year improvement [3] - The company has delivered an average earnings surprise of 8.3% over the trailing four quarters [3] Strategic Rationale - The acquisition of SoniVie is aimed at enhancing Boston Scientific's interventional cardiology therapy offerings, particularly in the hypertension space [2][4] - The TIVUS Intravascular Ultrasound System developed by SoniVie is designed for renal artery denervation (RDN), which can help regulate blood pressure [5] - The global renal denervation market was valued at $340.4 million in 2023 and is expected to grow at a compound annual growth rate of 40.2% through 2030 [7] Financial Impact of Acquisition - The transaction is expected to be slightly dilutive to Boston Scientific's adjusted EPS in 2025, but this will be offset by internal cost efficiencies [6] - On a GAAP basis, higher dilution is anticipated due to amortization expenses and acquisition-related charges, except for a one-time gain from the previously held equity interest in SoniVie [6] Future Prospects - The acquisition provides an opportunity for future innovation in the field of hypertension treatment, supported by strong clinical evidence and ongoing research [2] - Boston Scientific's strategy includes expanding its cardiovascular portfolio, as evidenced by a recent acquisition agreement with Bolt Medical, Inc. [9]

2025年2月5日， 波士顿科学 公布了 2024年第四季度及全年业绩 ， 第四季度销售额 45.61亿美元（约合332亿人民币） ，同比增长22.4%；全年总营收 167.47亿美元（约合1220亿人民币） ， 同比 增长17.6%。 # 财报亮点 第四季度的净销售额 为45.61亿美元 ，同比增长22.4%（报告）、23.1%（运营）和19.5%（有机）；每股收益（EPS）为0.38美元，同比增长11.8%，调整后 为0.70美元，同比增长27.3%； 毛利率为67.9%，同比下降130个基点；调整后为70.6%，同比增长20个基点；营业利润率为14.8%，同比下降90个基点；调整 后为27.4%，同比增长80个基点。 全年净销售额为167.47亿美元 ，同比增长17.6%（报告）、18.5%（运营）和16.4%（有机）；每股收益（EPS）为1.25美元，同比增长20.0%，调整后为2.51 美元，同比增长100.0%；毛利率为68.6%，同比下降90个基点；调整后为70.3%，同比下降40个基点；营业利润率为15.5%，同比下降100个基点，调整后为 27.0%，同比增长70个基点。 | Q4 & FY ...